NICE, the National Institute for Health and Care Excellence, plays a significant role in the cost per Quality-Adjusted Life Year (QALY) threshold debate. Learn more about NICE's contributions and ...

Outlook Therapeutics' Lytenava has become the first ophthalmic formulation of VEGF inhibitor bevacizumab to be cleared for use by the NHS in England and Wales for treating wet age-related macular ...